Galapagos to present new data at Ash 2023 fromongoing CD19 Car-t sudies

Galapago to present additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia, rrCLL , with or without Richter transformation, and non-Hodgkin lymphoma, rrNHL during two poster sessions at the 65th American Society of Hematology ASH Annual Meeting taking place in San Diego, from 9-12 December. Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancers Two poster presentations include recent data updates and additional data not included in the ASH abstracts